{"nct_id":"NCT03420742","title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","status":"COMPLETED","status_verified_date":"2022-04","start_date":"2019-06-26","start_date_type":"ACTUAL","primary_completion_date":"2020-03-24","primary_completion_date_type":"ACTUAL","completion_date":"2021-04-29","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["TAK"]}